The two newly approved direct-acting antiviral (DAA) therapies are dramatically changing the HCV treatment landscape. Through presentations and case vignettes, our expert faculty will show you why and how you should integrate the new DAA therapies into your clinical practice.

What do top-line, phase III clinical data mean for your patients?
What do we know about these therapies now that we did not know last spring?
Which patients can and should be offered the new therapies?
How can the complex prescribing information be translated into useable treatment protocols?
What practical tips can help you make the switch to the new standard-of-care therapies?


Disclaimer: Presented for attendees of the 62nd AASLD Annual Meeting (The Liver Meeting®). This event/function is sponsored by Projects In Knowledge and supported by Vertex Pharmaceuticals. This is not an official function/event of the American Association for the Study of Liver Diseases.